ACTengine Program Propels IMTX, Cannabics Pharma On Watch, TBIO Disappoints, All Eyes On PRQR
Today’s Daily Dose brings you news about Cannabics’ drug candidate RCC-33 prolonging survival rate in mice inoculated with human colorectal cancer cells, encouraging data of Immatics’ ACTengine program, and disappointing results from Translate Bio’s cystic fibrosis trial. Read on… 1. Cannabics’ Antitumor Drug Candidate RCC-33 Prolongs Survival in Mice Cannabics Pharmaceuticals Inc.’s (CNBX.OB) drug candidate RCC-33 prolonged survival rate in […]
Read more